

Oncology Screening in Post-Renal Transplant Patients: A retrospective review of adherence to screening guidelines in a Canadian health region

Roberta Al Housani, RN, BEd, MSN, CCTC¹; Dr. Peter Birks, MD, FRCPC, MHA²; Catherine Cheung, BSc(Pharm), ACPR, PharmD¹; Halle Golding¹; Dr. Faran Rashid¹; Randi Shen¹; Tarandeep Toor¹ ¹Fraser Health Pre/Post-Transplant Clinic, Surrey, BC, Canada; ²Nephrology and Internal Medicine, UBC Clinical Assistant Professor, Vancouver, BC, Canada

OBJECTIVE

- Evaluate the completeness of ageappropriate tests recommended to assess for possible cancer in transplant recipients care for by the Fraser Health Post Transplant Program, specifically reviewing recommended tests for colon, cervical, breast, and prostate cancer
- Identify any gaps in malignancy screening in this population that may inform change

CONTACT

Dr. Peter Birks Fraser Health Nephrology Peter.Birks@fraserhealth.ca

- population

- transplant team
- primary care practitioner

Study population: All adult post kidney transplant recipients, age 19-74, currently under the care of the Fraser Health Post Kidney Transplant Clinic as of May 8, 2021.

Data: Retrospective chart review using electronic medical records (Meditech, CareConnect, and BC Cancer Agency). Data collection went back retrospectively from May 8, 2021 until date of first kidney transplant. This study received approval by the Fraser Health Research Ethics Board.

Variables collected

- transplant team)

Complete screening was defined based on British Columbia Canada guidelines

- and older
- history of colon cancer

Incomplete screening defined as screening with lower frequency than recommended guidelines since transplant

INTRODUCTION

• Organ transplant is associated with an increased risk of malignancy as a result of immunosuppressive medications • Prior reviews found at least triple the rate in the general

 Patients diagnosed with cancer post-transplant have reduced survival, and treatment options may be limited by their kidney disease, medications, or comorbidities

 Malignancy diagnosis may necessitate modification of antirejection medications and affect graft survival

Screening to detect cancer early is critical

• The responsibility for cancer screening is center/region dependent and may include primary care providers versus the

• In BC, Canada, cancer screening is the responsibility of the

METHODS

 Completion of recommended oncology screening: Breast (mammogram), Cervical (PAP), Prostate (PSA), Colorectal (FIT) • Who ordered the test (Primary Care Practitioner versus

• PAP smear every 3 years for females sexually active or age 25-69

• Mammogram every 2 years for all females 50-74 years old • FIT test every 2 years for individuals age 50-74 with no family

• PSA annually for males age 50 and older





3. Hall, E.C., Pfeiffer, R.M., Segev, D.L., & Engels, E.A. Cumulative incidence of cancer after solid organ transplantation. Cancer 2013; 119(12), 2300-2308

DISCUSSION

High proportion of incomplete or absent cancer screening

• This is a current gap in care for a high risk transplant population • Possible explanations for poor adherence to concern screening guidelines may include:

- BC Cancer Agency data shows similarly low rates in general population for PAP and Mammogram
- Low comfort in managing the post transplant population amongst primary care practitioners
- High unattachment to family practitioner
- Family practitioner may sometimes be unclear whose responsibility it is to arrange cancer screening

Recommendations

A larger province-wide study

- Determine reasons why screening incomplete
- Identify barriers

 Creation of a patient handout re: post Tx oncology risks/screening, or update the current BC Transplant handout Health Guide for Patients after Transplantation

 Add cancer as cause of death to current BC Transplant statistics • Implementing a checklist system for post transplant clinics where due/overdue oncology screening is flagged and patients can be advised to complete

Education for GP's re: necessity of post Tx oncology screening

CONCLUSION

Solid organ transplant patients are at increased risk for malignancy and our study shows cancer screening is incomplete in our sample of transplant patients. There is much room for improvement. Further investigations will be needed to determine reasons why screenings are incomplete and to identify barriers to these important cancer screenings.

REFERENCES

1. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients. American Journal of Transplantation 2009; 9 (Suppl 3): S86-S88.

2. Webster AC, Craig JC, Simpson JM et al. Identifying high risk groups and quantifying absolute risk of cancer after kidney transplantation: A cohort study of 15,183 recipients. Am J Transplant 2007; 7: 2140-2151.